Phase 3 N=145 IDegLira HIGH Trial
Diabetes Mellitus
Primary: Change in Hemoglobin A1c (HbA1c) — -3.18; -3.00 percentage of HbA1c
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Early Phase 1 N=8 Development and Translation of Generator-Produced PET Tracer for Myocardial Perfusion Imaging-Dosimetry Group
Coronary Artery Disease
Primary: Organ Dosimetry — 0.109; 0.019; 0.012; 0.034 rad/mCi
N/A N=1,898 Aligning Pulse Oximetry With Guidelines
Bronchiolitis
Primary: Audit & Feedback Feasibility Using Adapted Item From Feasibility of Intervention Measure (FIM) — 222; 331; 86; 20 Participants
Phase 2 N=64 Injection Techniques of Collagenase Clostridium Histolyticum (CCH) for the Treatment of EFP (Cellulite)
Edematous Skin
Primary: Aesthetic Appearance Improvement Likert Scores by Treatment Region at Day 22 — 1.08; 1.10; 0.75; 0.50 score on a scale
Phase 3 N=510 A Study to Evaluate the Efficacy and Safety of Bismuth-Containing Quadruple Therapy With Oral Vonoprazan (TAK-438) 20 mg Compared to Esomeprazole 20 mg Twice Daily in Paticipants With Helicobacter Pylori Infection
Helicobacter Pylori
Primary: Percentage of Helicobacter Pylori Positive (HP+) Participants With Successful HP Eradication at Week 4 Post-Treatment — 86.8; 86.7 percentage of participants — p==0.0009
N/A N=101 Limited Market Release - MotionSense Clinical Use Evaluation
Knee Arthroplasty · Patient Engagement · Patient-Reported Outcome Measures (PROMs)
Primary: Evaluate Patient and Practice Compliance With the MotionSense Wearable System: Hours of MotionSense Use Per Day in Office
Phase 2 N=59 Study With Subjects 18-65 Years Old With Partial Onset Seizures Who Are Currently Taking Levetiracetam
Epilepsy, Partial
Primary: Percent Change From Baseline in Seizure Frequency Per Week for Partial Onset Seizures (Type I) by Visit and Overall by Period — -26.07; -32.05; -42.22; -31.67 percentage…
Phase 2 N=16 A Study to Evaluate the Abuse Potential of Oxymorphone Compared to Other Mu Opioid Agonists.
Opioid Use Disorder
Primary: Positive Subjective Drug Effects (i.e., Drug "Liking"). — 52.1; 57.5; 71.8; 71.5 units on a scale — p=.0001
Phase 2 N=52 Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer
Prostate Cancer
Primary: Objective Response Rate Measured by RECIST 1.1 — 7; 0 Participants
N/A N=240 Ancillary Study of the Lessening Incontinence With Low-impact Activity Study
Urinary Incontinence
Primary: Change From Baseline in One-legged Balance Test (Winsorized) — 1.34; 1.53 seconds — p=0.743
Phase 3 N=19 A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age and Have an Ivacaftor-Responsive CFTR Mutation
Cystic Fibrosis
Primary: Part A: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious (TEAEs) — 10; 1 Participants
N/A N=270 The Impact of the COVID-19 (SARS-CoV-2 Disease) on Psychopathology
Psychosis;Schizophrenic · Personality Disorders · Mood Disorders
Primary: Brief Psychiatric Rating Scale (BPRS) — 29.30; 32.80; 30.25 score on a scale
N/A N=191 Organic Diet Intervention in Primary School Children
Oxidative Stress · Inflammation
Primary: Change in Pesticide Metabolite 3-phenoxybenzoic Acid (3-PBA) Levels in Urine Between Organic and Conventional Periods* — 11.4 % change — p=<0.001
N/A N=11,234 Evaluation of a Letter Intervention Promoting a Plant-based Diet
Cardiovascular Diseases · Diabetes Mellitus · Obesity
Primary: Medical Cost in US Dollars From One Year Before to One Year After Intervention — 6123.39; 5863.82; 5901.99; 5630.26 dollars
N/A N=112 Physical Activity and Screen-Time Regulations in Childcare Centers - Aim 1
Childhood Obesity
Primary: Change in Environment and Policy Assessment and Observation (EPAO) Score and EPAO Subscales. — -.12; .21; .25; .21 minutes